For the quarter ending 2025-09-30, ALGS had $23,285K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -31,537 | 27,225 |
| Accretion of discount on investments | 710 | 1,034 |
| Non cash lease expense | 478 | 905 |
| Change in fair value of 2023 common warrants | 4,205 | -63,176 |
| Depreciation expense | 220 | 453 |
| Stock-based compensation including espp | 1,467 | 2,119 |
| Other assets | -587 | -190 |
| Accounts payable | 752 | 1,328 |
| Accrued liabilities | 1,400 | -3,352 |
| Operating lease liabilities | -796 | -1,499 |
| Deferred revenue | -411 | 428 |
| Net cash and cash equivalents used in operating activities | -24,345 | -36,413 |
| Maturities of short-term investments | 70,000 | 20,000 |
| Purchase of short-term investments | 22,124 | 103,336 |
| Purchases of property and equipment | -193 | -152 |
| Net cash and cash equivalents used in investing activities | 47,683 | -83,488 |
| Proceeds from issuance of common stock, common warrants and pre-funded warrants in connection with pipe offering, net of costs | -43 | 101,386 |
| Payments on finance lease | 10 | 1 |
| Proceeds from the espp purchase | 0 | 180 |
| Net cash and cash equivalents provided by financing activities | -53 | 101,565 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 23,285 | -18,336 |
| Cash and cash equivalents at beginning of period | 37,107 | - |
| Cash and cash equivalents at end of period | 42,056 | - |
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)